Cargando…
Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry
Development of first-generation thrombopoietins (TPOs) was halted due to antibodies that neutralized endogenous TPO, causing protracted thrombocytopenia in some patients. The second-generation TPO receptor agonist romiplostim, having no homology to TPO, was developed to circumvent potential immunoge...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153015/ https://www.ncbi.nlm.nih.gov/pubmed/34638135 http://dx.doi.org/10.1182/bloodadvances.2021005105 |